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Background—Serotonergic medications with various mechanisms of action are used to treat psychiatric disorders and are
being investigated as treatments for drug dependence. The occurrence of fenfluramine-associated valvular heart disease
(VHD) has raised concerns that other serotonergic medications might also increase the risk of developing VHD. We
hypothesized that fenfluramine or its metabolite norfenfluramine and other medications known to produce VHD have
preferentially high affinities for a particular serotonin receptor subtype capable of stimulating mitogenesis.
Methods and Results—Medications known or suspected to cause VHD (positive controls) and medications not associated
with VHD (negative controls) were screened for activity at 11 cloned serotonin receptor subtypes by use of
ligand-binding methods and functional assays. The positive control drugs were (6)-fenfluramine; (1)-fenfluramine;
(2)-fenfluramine; its metabolites (6)-norfenfluramine, (1)-norfenfluramine, and (2)-norfenfluramine; ergotamine;
and methysergide and its metabolite methylergonovine. The negative control drugs were phentermine, fluoxetine, its
metabolite norfluoxetine, and trazodone and its active metabolite m-chlorophenylpiperazine. (6)-, (1)-, and (2)-
Norfenfluramine, ergotamine, and methylergonovine all had preferentially high affinities for the cloned human serotonin
5-HT2B receptor and were partial to full agonists at the 5-HT2B receptor.
Conclusions—Our data imply that activation of 5-HT2B receptors is necessary to produce VHD and that serotonergic
medications that do not activate 5-HT2B receptors are unlikely to produce VHD. We suggest that all clinically available
medications with serotonergic activity and their active metabolites be screened for agonist activity at 5-HT2B receptors
and that clinicians should consider suspending their use of medications with significant activity at 5-HT2B receptors.
(Circulation. 2000;102:2836-2841.)
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The association of valvular heart disease (VHD) with theadministration of phentermine and fenfluramine (phen/
fen) and dexfenfluramine1 led to the withdrawal of fenflura-
mine and dexfenfluramine from the marketplace in Septem-
ber 1997. Well-controlled echocardiographic prevalence
studies of VHD in clinically asymptomatic patients who had
taken appetite suppressants report varying case rates, ranging
from no statistically significant increase compared with
control subjects2,3 to moderate4,5 and substantially increased6
case rates. Using a clinical end-point, Jick et al7 reported that
the use of either fenfluramine or dexfenfluramine was asso-
ciated with a cumulative 5-year incidence of newly diagnosed
VHD, primarily aortic regurgitation, of 35 cases per 10 000,
indicating that the risk of developing clinically significant
valve disease is low. The lack of any VHD cases associated
with the use of phentermine alone, along with the fact that
VHD occurs in users of both phen/fen and dexfenfluramine,
suggests that fenfluramine is the likely cause of the VHD.
Fenfluramine (Pondimin) is a racemic mixture of 2 enan-
tiomers. (1)-Fenfluramine, also called dexfenfluramine, was
marketed under the trade name Redux. Fenfluramine and
dexfenfluramine are metabolized to (6)-norfenfluramine and
(1)-norfenfluramine, respectively.8 A major action of fenflu-
ramine and its metabolites is to release neuronal serotonin
(5-HT) via a carrier-mediated exchange mechanism.9 In
addition, fenfluramine and norfenfluramine have direct ago-
nist actions at certain 5-HT receptors, in particular members
of the 5-HT2 receptor family.10 Phentermine, conversely,
preferentially releases dopamine.9
Serotonergic medications with various mechanisms of
action are widely used to treat psychiatric disorders and are
being investigated as treatments for drug dependence, gastro-
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intestinal disorders, and hypertension. Fenfluramine-
associated VHD has led some to propose caution “in the
long-term use of other agents that act on serotonergic mech-
anisms, albeit by different pathways.”11 Uncritical acceptance
of this proposal would significantly affect the treatment of
psychiatric patients as well as hinder the development of new
therapeutics. Thus, determining the mechanism of
fenfluramine-associated VHD is likely to not only shed light
on the adverse effects of this particular medication but also
clarify whether this side effect might occur with other
medications that act via serotonergic mechanisms.
Perhaps by analogy with the ability of fenfluramine to
increase synaptic levels of 5-HT,9 investigators proposed that
fenfluramine produces VHD via a serotonergic mechanism:
increases in plasma 5-HT (see review12). However, as noted
elsewhere, fenfluramine decreases platelet and plasma 5-HT
in animals and humans, and phen/fen treatment lowers
plasma 5-HT in humans.13 Therefore, another explanation
must be sought to clarify how fenfluramine could cause
VHD.
In light of the established role of 5-HT as a mitogen,14 we
undertook the present study to determine whether fenflura-
mine [(6)-fenfluramine, (1)-fenfluramine, (2)-
fenfluramine] or its metabolites [(6)-norfenfluramine, (1)-
norfenfluramine, (2)-norfenfluramine] might activate
mitogenic 5-HT receptors. Several other drugs were included
in the study to provide both positive and negative controls.
Additional “positive controls” included methysergide, its
active metabolite methylergonovine,15 and ergotamine. Me-
thysergide and ergotamine are well known to produce pri-
marily left-sided VHD affecting the mitral valve.16,17 Nega-
tive controls included phentermine, fluoxetine, and its
metabolite norfluoxetine, which have not been associated
with VHD. We included the antidepressant trazodone and its
active metabolite m-chlorophenylpiperazine (mCPP) as an
additional negative control. In addition to having activity at a
wide range of 5-HT receptors,18 mCPP shares with fenflura-
mine the ability to release brain 5-HT via a carrier-mediated
exchange mechanism.19 Trazodone is not associated with
VHD. Our working hypothesis was that the “positive control”
drugs would share in common the ability to activate a
particular 5-HT receptor expressed in heart valves that is
mitogenic, and that the “negative control” drugs would not.
We called this the commonly activated serotonin receptor, or
CASR.
Methods
Materials
The National Institute of Mental Health’s Chemical Synthesis and
Drug Supply Program provided the following compounds: (6)-
norfenfluramine, (1)-norfenfluramine, and (2)-norfenfluramine.
(6)-Fenfluramine and (1)-fenfluramine were obtained from the
NIDA Drug Supply Program (Rockville, Md). (2)-Fenfluramine,
fluoxetine, and norfluoxetine were purchased from Research Bio-
chemicals Inc. Phentermine, mCPP, methysergide, and methyler-
gonovine were purchased from Sigma Chemical Co. Trazodone was
supplied by the NIMH Psychoactive Drug Screening Program.
Radioligand Binding Assays and Sources of
cDNA Clones
Radioligand binding assays for 5-HT receptors were performed as
previously detailed with cloned human (5-HT1A, 5-HT1B, 5-HT1D,
5-HT1E, 5-HT2B, 5-HT5A, 5-HT6, 5-HT7) or rat (5-HT2A, 5-HT2C)
cDNAs expressed in COS-7 cells.20 The h5HT1A cDNA was obtained
from John Raymond (Medical University of South Carolina), the
h5-HT1B, h5HT1D, h5HT6, and h5HT7 cDNAs were from Mark
Hamblin (University of Washington), the rat 5HT2A and rat 5HT2C
cDNAs were from David Julius (University of California San
Francisco), and the h5HT5A cDNA was from Rene Hen (Columbia
University).
The h5-HT2B cDNA was obtained by amplification from human
brain cDNA (Quickclone cDNA; Clonetech) with Pfu polymerase
and subcloned in-frame into the pTag2A eukaryotic expression
vector (Stratagene). The h5HT1E cDNA was obtained by amplifica-
tion of human genomic DNA (Clonetech) with Pfu polymerase and
subcloned into the pcDNA3.0 eukaryotic expression vector. The
sequences of the h5HT2B and h5HT1E cDNAs were verified by
automatic DNA sequencing (Cleveland Genomics, Inc). Detailed
protocols for transfection, using FUGENE6, as well as complete
details of all the radioligand binding assays, are available.20,21a
For initial screening, compounds were tested at concentrations of
10 mmol/L; Ki determinations using 7 concentrations of unlabeled
ligand spanning 4 orders of magnitude were obtained on compounds
that gave .50% inhibition at 10 mmol/L. Ki values were calculated
with the LIGAND program as previously detailed.20–23
Functional Assays: Phosphoinositide Hydrolysis
Phosphoinositide hydrolysis assays were performed with stably
(5-HT2A, 5-HT2C) or transiently (5-HT2B) expressed receptors plated
in 24-well culture plates as previously detailed.21b,22 In brief,
transfected cells were loaded with [3H]inositol (15 Ci/mmol; 1
mCi/mL) overnight in inositol-free DMEM without serum. The next
day, 3H-inositol phosphate accumulation assays were performed in a
modified Krebs-bicarbonate buffer as previously detailed. Kact
(nmol/L) and percent Vmax (relative to 5-HT) values were calculated
as previously described.21b–23
Results
Figure 1 reports the results of the initial screen of compounds
in the ligand-binding assays. On the basis of these results, Ki
values were determined for selected compounds. The fenflu-
ramines and norfenfluramines had Ki values ranging from 673
to 1950 nmol/L and lacked agonist activity at the 5-HT1A
receptor (data not shown). The other positive control drugs
(methysergide, ergotamine, and methylergonovine) had high
affinities for the 5-HT1A site and were full and potent agonists
(data not shown). This pattern of results, along with the fact
that clinically used 5-HT1A agonists, such as buspirone, are
not associated with VHD, suggests that the 5-HT1A receptor is
not the CASR.
The fenfluramines and norfenfluramines had low affinity
for the 5-HT1D, 5-HT1B, and 5-HT1E receptors (data not
shown), and the other positive-control compounds had high
affinities for these sites. Because of the low affinity of the
fenfluramines for these sites, we did not conduct functional
activity studies. The low affinities of the fenfluramines for the
h5-HT1D/1B receptors, coupled with the observation that
sumatriptan, a potent 5-HT1D/1B agonist24 widely used for
treating migraine headaches, is not associated with VHD,
suggests that the 5-HT1D/1B receptors do not mediate
fenfluramine-associated VHD.
The ergot compounds had high affinity for the 5-HT2A,
5-HT2B, and 5-HT2C receptors (Table 1). With regard to the
5-HT2A receptor, ergotamine was a full agonist, methysergide
was a weak partial agonist, and methylergonovine was a
potent, full agonist (Table 2). The fenfluramines had micro-
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molar affinity for the 5-HT2A receptor. Although the fenflu-
ramines were weak partial agonists, the norfenfluramines
were somewhat more potent partial agonists. The relatively
low affinity of the norfenfluramines at the 5-HT2A receptor
suggests that this site is not the CASR.
The norfenfluramines were moderately potent at the
5-HT2C receptor and were full agonists. The fenfluramines
were also full agonists but were significantly less potent than
the norfenfluramines. Among the other positive-control test
drugs, methysergide and methylergonovine had high affinity
for the 5-HT2C receptor, with methysergide being a weak
partial agonist and methylergonovine being a potent full
agonist. Ergotamine, conversely, was a potent partial agonist.
mCPP, a negative control drug, was a potent full agonist at
the 5-HT2C receptor. As reported previously,25 fluoxetine and
its metabolite were moderate-potency antagonists. The obser-
vation that human heart valves have very low levels of this
receptor10 strongly suggests that the 5-HT2C receptor is not the
CASR.
The norfenfluramines had high affinity (10 to 50 nmol/L)
for the 5-HT2B receptor, in confirmation of recent studies.10,26
Functional studies demonstrated that the norfenfluramines
were full agonists at the 5-HT2B site (Figure 2). The fenflu-
ramines, in contrast, bound to the 5-HT2B receptor with Ki
values of ’5 mmol/L. Ergotamine was a potent partial
agonist, and methysergide was a very-low-efficacy partial
agonist at the 5-HT2B receptor. Methylergonovine was a
high-affinity partial agonist. Among the negative control
drugs, mCPP was a moderate-potency partial agonist with the
same efficacy as methylergonovine. With the exception of the
findings with mCPP, these findings suggest that the 5-HT2B
receptor may be the CASR. Trazodone, which binds with
high affinity to the 5-HT2B receptor (Table 1), is a potent
5-HT2B antagonist (data not shown).
The fenfluramines and norfenfluramines were inactive at
the 5-HT5 and 5-HT6 receptors (data not shown), indicating
that these receptors are most likely not the CASR. Although
the norfenfluramines have moderate affinity at the 5-HT7
receptor, ergotamine had low affinity for this site, suggesting
that the 5-HT7 receptor is not the CASR (data not shown).
Phentermine was inactive at all 5-HT receptors assayed here.
Figure 1. 3D representation of initial screen of compounds in ligand-binding assays. Data show mean percent inhibition of specific
binding (along z axis) at all tested neurotransmitter receptors and channels (along x axis) by 10 mmol/L concentration of test agents
(along y axis). Left arrow shows location of 5-HT2–family receptors and fenfluramine analogues; right arrow shows location of phenter-
mine and adrenergic receptors. Human clones were used except where noted: 5-HT1A indicates 5HT1A serotonin receptor; 5-HT1Da,
5HT1D serotonin receptor; 5-HT1Db, 5HT1B serotonin receptor; 5-HT1E, 5HT1E serotonin receptor; r5HT2A, rat 5HT2A serotonin receptor;
5-HT2B, 5HT2B serotonin receptor; r5HT2C, rat 5-HT2C serotonin receptor; 5-HT3, mouse 5HT3 receptor; 5-HT5A, 5HT5A serotonin
receptor; 5-HT6, 5HT6 serotonin receptor; 5-HT7, 5HT7 serotonin receptor; H1, histamine H1 receptor; NMDA, NMDA glutamate recep-
tor; VMAT2, vesicular monoamine transporter type II; SERT, serotonin transporter; NET, norepinephrine transporter; bDAT, bovine
dopamine transporter; GABA-A, rat GABA-A receptor; rBZP, rat benzodiazepine binding site; Alpha2A, a2A-adrenergic receptor;
Alpha2B, a2B-adrenergic receptor; Alpha2C, a2C-adrenergic receptor; rBeta1, rat b1-adrenergic receptor; rBeta2, rat b2-adrenergic
receptor; alpha1A, rat a1A-adrenergic receptor; V1, vasopressin-1 receptor; V2, vasopressin-2 receptor; and V3, vasopressin-3 receptor.
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Discussion
The study reported here examined the interaction of 9
medications that are associated with VHD (positive controls)
and 5 medications that are not associated with VHD (negative
controls) at 11 cloned 5-HT receptors. We sought to identify
a mitogenic 5-HT receptor that would be activated by the
positive but not the negative controls. We hypothesized that
this CASR mediates fenfluramine-associated VHD. Among
the receptors assayed, the 5-HT2B receptor has 5 characteris-
tics consistent with its being the CASR: (1) it is located on
both mitral and aortic valves10; (2) it mediates mitogenisis27;
(3) the norfenfluramines have high affinity and efficacy at the
5-HT2B receptor; (4) ergotamine and methylergonovine, the
active metabolite of methysergide, are high-affinity partial
agonists for the 5-HT2B receptor; and (5) with the exception of
mCPP (see below), the negative control drugs (fluoxetine,
norfluoxetine, phentermine) have very low affinity for this
site and lack agonist effects at this receptor. The 5-HT2C
receptor is ruled out as the CASR, primarily because few of
these receptors are expressed in heart valves.10
There are several observations that, at first glance, are
difficult to reconcile with the hypothesis that the 5-HT2B
receptor mediates the valvulopathy associated with adminis-
tration of fenfluramine, ergotamine, and methysergide. First,
whereas (1)-fenfluramine produces primarily aortic regurgi-
tation,4,7 ergotamine and methysergide produce primarily
mitral regurgitation.16 Given that 5-HT2B receptors are found
on both valves,10 the mechanism underlying the anatomic
specificity of the valvulopathy associated with these 2 classes
of drugs is enigmatic. Second, methysergide appears to
produce a more severe form of VHD than fenfluramine.
Patients with fenfluramine-associated VHD are clinically
asymptomatic and typically do not have audible heart mur-
murs.2 The best estimate of the incidence of clinically
significant fenfluramine-associated VHD is 0.07% per year.7
In contrast, patients treated with methysergide developed
clinically significant VHD, including new heart murmurs,16
with an incidence of 3%.16 Thus, although methylergonovine
is a less effective agonist at the 5-HT2B receptor than
norfenfluramine, it produces a more severe form of VHD in
a greater number of patients. Third, methysergide adminis-
tration is associated with fibrosis of other anatomic sites in
addition to heart valves.28 In contrast, fenfluramine-
associated fibrosis appears to be localized to heart valves.
Fourth, the finding that mCPP has activity at 5-HT2B
receptors must be reconciled with observations that traz-
TABLE 1. Ki Values of Test Drugs at 5-HT2 Receptors
Drug
Rat
5-HT2A
Human
5-HT2B
Rat
5-HT2C
(6)-Fenfluramine 5 21662.5 41346753 31836374
(1)-Fenfluramine 11 10761354 50996690 62456514
(2)-Fenfluramine 54636352 571361344 34156542
(6)-Norfenfluramine 23166163 52.1612.3 557636
(1)-Norfenfluramine 1516688 11.264.3 32467.1
(2)-Norfenfluramine 38416361 47.8618.0 814658
Ergotamine 9.060.6 3.060.2 12.060.9
Methysergide 15.062.4 9.162.9 1.860.1
Methylergonovine 12.660.6 0.4960.09 12.460.6
Fluoxetine 299631 503061152 50.065.9
Norfluoxetine 638663 506361161 286635
Trazodone 19.861.4 73.6621.17 402626
mCPP 391627 3.260.6 5966.5
5-HT 614643 4.061.1 12.260.8
Phentermine .10 000 .10 000 .10 000
Values are mean6SEM (n53). Units are nanomolar.
TABLE 2. Functional Activity of Test Drugs at 5-HT2 Receptors
Drug Human 5-HT2A Human 5-HT2B Human 5-HT2C
(6)-Fenfluramine
Kact 4 131614 400 ND ND
Vmax 1562.35
(1)-Fenfluramine
Kact .10 000 379670 362664
Vmax ND 3868.2 8065.9
(2)-Fenfluramine
Kact 5 2796587 12486252 360691
Vmax 4364.2 4762.9 8467.4
(6)-Norfenfluramine ND ND ND
(1)-Norfenfluramine
Kact 6306141 18.465.3 1362.4
Vmax 8865.3 7363.5 10066.5
(2)-Norfenfluramine
Kact 1 5656190 3576105 1865.3
Vmax 9365.3 7168.8 80610
Ergotamine
Kact 1662.3 9.861.8 561.76
Vmax 7561.8 5661.8 7568.8
Methysergide
Kact 3.561.00 150625 2.960.9
Vmax 2461.76 1862.4 3362.0
Methylergonovine
Kact 1.360.2 0.860.3 2.560.7
Vmax 7064.1 4061.8 10364.1
Fluoxetine ND ND Antagonist
Ki56166101
Norfluoxetine ND ND Antagonist
Ki543610
Trazodone Antagonist Antagonist Antagonist
mCPP
Kact 65610 64615 0.6460.17
Vmax 5566.5 4368.2 7968.8
5-HT
Kact 66615 2.460.9 0.660.1
Vmax 100 100 100
Phentermine
Kact ND ND 13946264
Vmax 6665.9
Values are mean6SEM (n53). Kact values are nmol/L6SEM; Vmax values are
% of 5-HT6SEM. ND indicates not done.
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odone, from which it is metabolically derived, is not associ-
ated with VHD. Therapeutic doses of trazodone generate
plasma levels of mCPP from 150 to 550 nmol/L,29 which are
in the range needed to activate 5-HT2B receptors. However,
trazodone is a potent 5-HT2B receptor antagonist, and its
plasma levels are ’5-fold higher than that of mCPP.29 Thus,
trazodone would act to block activation of 5-HT2B receptors
by mCPP.
Thus, a possible explanation for the differing degrees of
VHD prevalence seen among the 5-HT2B agonists is the
degree of 5-HT2B antagonism produced by either parent drug
or metabolites. Methysergide, as a very-low-efficacy 5-HT2B
agonist, would act to antagonize the agonist effects of
methylergonovine (Table 2). However, methysergide is rap-
idly metabolized to methylergonovine, is more rapidly elim-
inated, and achieves blood levels 10-fold lower than methy-
ergonovine.15 Because the agonist actions of
methylergonovine are most likely not significantly blocked
by its parent drug, methysergide administration would prob-
ably cause a higher prevalence of VHD. In the case of
fenfluramine, (1)-fenfluramine and (2)-fenfluramine have
lower efficacy (’40%) at the 5-HT2B receptor than (1)-
norfenfluramine (75%) and achieve blood levels twice that of
norfenfluramine.8 This indicates that the parent drugs would
partially antagonize activation of 5-HT2B receptors by (1)-
norfenfluramine. This may explain why the fenfluramines
appear to produce a less severe form of VHD than methyser-
gide (see above).
Taken at face value, the 5-HT2B hypothesis predicts that
elevations of plasma 5-HT should produce valvulopathy in
both the aortic and mitral valves. Indeed, 5-HT is the most
potent and efficacious agonist at the 5-HT2B receptor. Medi-
cations such as lithium and monoamine oxidase inhibitors
produce sustained 2-fold increases in plasma 5-HT and are
not associated with VHD.30,31 This suggests that modest
elevations of plasma 5-HT are unlikely to produce this
adverse effect. Patients with carcinoid syndrome develop
extremely high levels of plasma 5-HT (.500 nmol/L32), and
fibrotic valve lesions occur exclusively on the right side of
the heart. Although some attribute the lack of left-sided VHD
in carcinoid syndrome to the almost complete removal of
plasma 5-HT by the lung before the blood empties into the
left atrium,12 this hypothesis fails to take into account the fact
that the blood samples taken for analysis of 5-HT are
withdrawn from the antecubital vein in the arm, the blood of
which is derived most directly from the left side of the heart.
Although the right side of the heart is undoubtedly bathed in
higher concentrations of 5-HT than the left side, the left side
is clearly exposed to 5-HT concentrations well in excess of
that necessary to completely activate the 5-HT2B receptor.
Thus, it is not clear why carcinoid syndrome produces fibrotic
lesions on the valves of the right side of the heart, whereas
fenfluramine, methysergide and ergotamine affect primarily
the valves of the left side.
Viewed collectively, these considerations suggest that
activation of 5-HT2B receptors may be necessary to produce
VHD. Clearly, other factors also determine the susceptibility
of an individual to develop the lesion, its anatomic location,
and its severity. Despite our lack of knowledge of what these
factors might be, these data suggest that serotonergic medi-
cations, which do not activate 5-HT2B receptors, are unlikely
to produce VHD. These findings further suggest that the
simplest pathogenic mechanism to explain anorexigen-
associated VHD is a direct activation of 5-HT2B receptors by
norfenfluramine. This mechanism does not necessitate the
formulation of unlikely synergistic mechanisms between
phentermine and fenfluramine33 or a role for plasma 5-HT to
explain the occurrence of VHD. Finally, on the basis of these
results and those recently reported by Fitzgerald et al,10 we
suggest that all clinically available medications with seroto-
nergic activity and their metabolites should be screened for
agonist activity at 5-HT2B receptors.
Note Added in Proof
Dr Roth’s laboratory has begun to measure the efficacies of
clinically used serotonergic compounds at the h5-HT2B
receptor and have not yet found any that are agonists.
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